B+
Bull case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
PROF
Profound MedicalANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$7.25
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.25
Analysis reference price unavailable
Analysis 2026-04-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-18
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+86.2
Score
AI commentary
Sentiment is neutral-to-cautious. The evidence base is primarily filing-driven, not news-driven, and the deterministic prior is neutral with only middling evidence quality. The 10-K supports real revenue progress and adequate near-term liquidity, but forward visibility still looks limited enough that this remains a monitoring memo rather than a strong directional call.
RankAlpha Sentiment Codex - 2026-04-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07eventQ1 2026 results and business update on May 7, 2026High impact
Profound said on April 16, 2026 that it plans to release first-quarter 2026 financial results after market close on May 7, 2026 and host a call the same day; this is the next hard read-through on TULSA-PRO placement and utilization trends [#8-K-2026-04-16].
2026-12-31catalystTULSA-PRO recurring revenue conversion remains the core operating proof pointHigh impact
The 10-K says Profound uses a hybrid model with capital sales plus one-time-use devices and services, is building direct sales teams to increase utilization, and expects recurring revenues from devices, clinical support and maintenance; 2025 revenue was $16.1M, including $9.73M recurring non-capital revenue versus $8.24M in 2024, which supports a commercialization-monitoring thesis rather than a breakout thesis [#10-K-2026-03-05].
2027-03-05catalystCash runway reduces near-term financing pressure but does not remove execution riskHigh impact
Profound ended 2025 with $59.7M of cash after December 2025 equity raises and said existing cash plus product sales should fund operating expenses and capex for at least 12 months from the March 5, 2026 filing date; that de-risks immediate dilution, but the company also posted a $40.3M net loss and higher commercialization spending, so investors still need to see operating leverage [#10-K-2026-03-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-18 • Updated nightlySource: Internal modelMethodology